Abstract:Endogenous vascular endothelial growth factor (VEGF-A) can protect retinal ganglion cells (RGC) from stress-induced cell death in ocular hypertensive glaucoma. To exploit the neuroprotective function of VEGF-A for therapeutic application in ocular disorders such as glaucoma while minimizing unwanted vascular side effects, we engineered two novel VEGF variants, eVEGF-38 and eVEGF-53. These variants of the diffusible VEGF-A isoform VEGF121 are expressed as dimeric concatamers and remain tethered to the cell membrane, thus restricting the effects of the engineered VEGF to the cells expressing the protein. For comparison, we tested a Myc-tagged version of VEGF189, an isoform that binds tightly to the extracellular matrix and heparan sulfate proteoglycans at the cell surface, supporting only autocrine and localized juxtacrine signaling. In human retinal endothelial cells (hREC), expression of eVEGF-38, eVEGF-53, or VEGF189 increased VEGFR2 phosphorylation without increasing expression of pro-inflammatory markers, relative to VEGF165 protein and vector controls. AAV2-mediated transduction of eVEGF-38, eVEGF-53, or VEGF189 into primary mouse RGC promoted synaptogenesis and increased the average total length of neurites and axons per RGC by ~ 12-fold, an increase that was mediated by VEGFR2 and PI3K/AKT signaling. Expression of eVEGF-38 in primary RGC enhanced expression of genes associated with neuritogenesis, axon outgrowth, axon guidance, and cell survival. Transduction of primary RGC with any of the membrane-associated VEGF constructs increased survival both under normal culture conditions and in the presence of the cytotoxic chemicals H 2 O 2 (via VEGFR2/PI3K/AKT signaling) and N -methyl- d -aspartate (via reduced Ca 2+ influx). Moreover, RGC number was increased in mouse embryonic stem cell-derived retinal organoid cultures transduced with the eVEGF-53 construct. The novel, engineered VEGF variants eVEGF-38 and eVEGF-53 show promise as potential therapeutics for retinal RGC neuroprotection when delivered using a gene therapy approach.

RNA‐binding protein ELAVL1‐mediated neuroprotection of retinal ganglion cells

Long-Term Rescue Of Rat Retinal Ganglion Cells And Visual Function By Aav-Mediated Bdnf Expression After Acute Elevation Of Intraocular Pressure

Lentiviral vector-mediated expression of C3 transferase attenuates retinal ischemia and reperfusion injury in rats

AAV-NDI1 Therapy Provides Significant Benefit to Murine and Cellular Models of Glaucoma

Adeno-Associated Virus Mediated Sod Gene Therapy Protects the Retinal Ganglion Cells from Chronic Intraocular Pressure Elevation Induced Injury Via Attenuating Oxidative Stress and Improving Mitochondrial Dysfunction in A Rat Model

The Effect of A2AReceptor Antagonist on Microglial Activation in Experimental Glaucoma

Scaav2-Mediated C3 Transferase Gene Therapy in a Rat Model with Retinal Ischemia/Reperfusion Injuries

Rescue of retinal ganglion cells in optic nerve injury using cell-selective AAV mediated delivery of SIRT1

Novel engineered, membrane-localized variants of vascular endothelial growth factor (VEGF) protect retinal ganglion cells: a proof-of-concept study

AAV-mediated Expression of CNTF Promotes Long-Term Survival and Regeneration of Adult Rat Retinal Ganglion Cells

AAV-mediated Transfer of RhoA Shrna and CNTF Promotes Retinal Ganglion Cell Survival and Axon Regeneration

Protective Effects of Pituitary Adenylate-Cyclase-Activating Polypeptide on Retinal Vasculature and Molecular Responses in a Rat Model of Moderate Glaucoma

Neuritin 1 Drives Therapeutic Preservation of Retinal Ganglion Cells in an Ex Vivo Human Glaucoma Model

Inhibition of the Leucine-Rich Repeat Protein Lingo-1 Enhances RGC Survival in Optic Nerve Injury

[Neuroprotective Effect of Raav-Mediated Rhbdnf Gene Transfection on Rabbit Retina Against Acute High Intraocular Pressure].

Inner retinal injury in experimental glaucoma is prevented upon AAV mediated Shp2 silencing in a caveolin dependent manner

Viral Delivery of Multiple Mirnas Promotes Retinal Ganglion Cell Survival and Functional Preservation after Optic Nerve Crush Injury

Neuro-protection of Retinal Stem Cells Transplantation Combined with Copolymer-1 Immunization in a Rat Model of Glaucoma

Intravitreal Neuroglobin Mitigates Primate Experimental Glaucomatous Structural Damage in Association with Reduced Optic Nerve Microglial and Complement 3-Astrocyte Activation

Overexpression of S100A4 Protects Retinal Ganglion Cells Against Retinal Ischemia-Reperfusion Injury in Mice

SIRT1 is Required for the Neuroprotection of Resveratrol on Retinal Ganglion Cells after Retinal Ischemia-Reperfusion Injury in Mice